Aktis Oncology, Inc. Common stock
$21.88
-$0.98 (-4.29%)
$21.88Day Range$23.09
Key Statistics
Market Cap
$1.22B
Shares Outstanding
55.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 9, 2026
Round Lot
100
Locale
US
Trading Data
Day Open
$22.86
Day High
$23.09
Day Low
$21.88
Volume
2.73M
VWAP
$22.04
Prev Close
$22.86
Transactions
--
Acc. Volume
--
About Aktis Oncology, Inc. Common stock
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
PHARMACEUTICAL PREPARATIONSSIC 283479 employees17 DRYDOCK AVENUE, BOSTON, MA, 02210978-237-4380IPO Jan 9, 2026US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002035832
- Composite FIGI
- BBG00ZQS8KZ1
- Share Class FIGI
- BBG00ZQS8L07
- Ticker Root
- AKTS
- SIC Code
- 2834
About Aktis Oncology, Inc. Common stock (AKTS) Stock
Aktis Oncology, Inc. Common stock (AKTS) closed the 2026-09-18 session at $21.88, down 4.29% versus the previous close (-0.98). The stock opened at $22.86 and traded between $21.88 and $23.09 during that session. Session trading volume was 2.7M shares. The volume-weighted average price (VWAP) is $22.04.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Aktis Oncology, Inc. Common stock has a market capitalization of $1.22 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AKTS is listed on the XNAS exchange. The company employs approximately 79 people. Aktis Oncology, Inc. Common stock is headquartered in BOSTON, MA. The recorded listing date is 2026-01-09.
On this page you can find market AKTS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.